Subsidy Information and Financing Scheme MAFVedolizumab (Entyvio) Infusion 300 mg Additional clinical criteria applies Treatment of adults with moderately to severely active Crohn’... See all × MAFVedolizumab (Entyvio) Infusion 300 mg Additional clinical criteria applies Treatment of adults with moderately to severely active Crohn’s disease who have failed both conventional therapy and anti-TNFα biologics.
Drug Guidance for Subsidy 01/07/2022 Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease The Ministry of Health’s Drug Advisory Committee has recommended: Tofacitinib 5 mg tablet for... See all × 01/07/2022 Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease The Ministry of Health’s Drug Advisory Committee has recommended: Tofacitinib 5 mg tablet for treating adults with moderately to severely active ulcerative colitis (UC) who have failed conventional therapy and/or anti-TNFα biologics; and Vedolizumab 300 mg/vial powder for concentrate for solution for infusion for treating adults with moderately to severely active Crohn’s disease (CD) who have failed both conventional therapy and anti-TNFα biologics. Subsidy status RTofacitinib 5 mg tablets and vedolizumab 300 mg/vial powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. RTofacitinib and vedolizumab should be used in line with the clinical criteria for initial and continuing prescriptions for patients with UC and CD in the respective MAF checklists. RListing on MAF will be implemented on 1 July 2022. NRMAF assistance does not apply to any formulations or strengths of ustekinumab for treating CD and UC. 02/01/2019 Vedolizumab for treating ulcerative colitis and Crohn’s disease NRThe Ministry of Health’s Drug Advisory Committee has not recommended listing vedolizumab on ... See all × 02/01/2019 Vedolizumab for treating ulcerative colitis and Crohn’s disease NRThe Ministry of Health’s Drug Advisory Committee has not recommended listing vedolizumab on the Medication Assistance Fund (MAF) for treating ulcerative colitis and Crohn’s disease because of unacceptable cost-effectiveness compared with biosimilar infliximab at the price proposed by the manufacturer.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Entyvio Infusion 300 mg Changi General Hospital Khoo Teck Puat Hospital National University Hospital Singapore General Hospital Tan Tock Seng Hospital
INTRAVENOUS Select a brand starting with the letter: E ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL [SIN14950P]
SUBCUTANEOUS Select a brand starting with the letter: E ENTYVIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 108MG/0.68ML [SIN16673P]